Elevated levels of RhoA are reported in the ONH of human eyes with glaucoma [66], and Rho kinase (ROCK) inhibitors are increasingly recognised as a promising therapeutic strategy for the treatment of glaucoma, indicating shared pathology [184]. This evidence concerns the gene RHOA and glaucoma.